Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status
Authors' conclusion
The average weight reduction in this cohort was lower than that observed in the main phase 3 trials, likely because of higher rates of discontinuation and lower maintenance dosages.
Study context
- Population
- Adults with overweight or obesity without T2D who initiated injectable semaglutide or tirzepatide 2021–2023, large health system in Ohio and Florida6,109 semaglutide, 1772 tirzepatide
- Participants
- 7,881 adults
- Exposure
- Early vs late discontinuation vs non-discontinuation of semaglutide or tirzepatide
- Outcome
- Percentage change in body weight by discontinuation status
- Follow-up
- 12 months
Methodological detailselectronic health record data
- Electronic health record data
Main finding
As reported in the abstract
Percentage weight reduction · 1 year
Early discontinuation
3.6%
mean · SD 8.1%
Late discontinuation
6.8%
mean · SD 9.1%
Non-discontinuation
11.9%
mean · SD 9.2%
P < 0.001
- Overall mean (SD) percentage weight reduction
- 8.7% (9.6%)
Observational data: associations, not effects.
Further findings
Mean, %
| Outcome | Early discontinuation | Late discontinuation | Non-discontinuation | P value |
|---|---|---|---|---|
| Absolute reduction in percent HbA1c (prediabetes at baseline) · 1 yearEarly discontinuation vs Non-discontinuation · across the three discontinuation groups | 0.1 (SD 0.4) | 0.2 (SD 0.4) | 0.4 (SD 0.4) | P < 0.001 |
Low maintenance dosages
- Patients with low maintenance dosages
- 80.8%
Original publication
Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity (Silver Spring). Published 10 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →